BLU Stock Overview
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BELLUS Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$14.74 |
| 52 Week High | CA$14.76 |
| 52 Week Low | CA$6.38 |
| Beta | -0.28 |
| 1 Month Change | 1.24% |
| 3 Month Change | 104.72% |
| 1 Year Change | 47.11% |
| 3 Year Change | 24.60% |
| 5 Year Change | 867.73% |
| Change since IPO | -98.95% |
Recent News & Updates
Recent updates
Bellus: Expected Phase 3 Start Makes This A Long-Term Play
Sep 07BELLUS details late-stage plans for cough candidate after FDA meeting
Jul 12BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients
Dec 14Bellus Health - Betting Big On Chronic Cough Treatment
Aug 27BELLUS Health EPS misses by $0.06
May 10BELLUS Health establishes $50M at-the-market facility
Dec 23Shareholder Returns
| BLU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.2% | 1.7% |
| 1Y | 47.1% | 6.0% | 26.3% |
Return vs Industry: BLU exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: BLU exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| BLU volatility | |
|---|---|
| BLU Average Weekly Movement | 28.0% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BLU's share price has been volatile over the past 3 months.
Volatility Over Time: BLU's weekly volatility has increased from 15% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 74 | Roberto Bellini | www.bellushealth.com |
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.
BELLUS Health Inc. Fundamentals Summary
| BLU fundamental statistics | |
|---|---|
| Market cap | US$1.87b |
| Earnings (TTM) | -US$86.79m |
| Revenue (TTM) | US$15.00k |
Over9,999x
P/S Ratio-21.5x
P/E RatioIs BLU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLU income statement (TTM) | |
|---|---|
| Revenue | US$15.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$15.00k |
| Other Expenses | US$86.80m |
| Earnings | -US$86.79m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -578,586.67% |
| Debt/Equity Ratio | 0% |
How did BLU perform over the long term?
See historical performance and comparison